于相芬,孫宇新,孫振曉*
(1 山東省臨沂市精神衛(wèi)生中心精神科,山東臨沂276005;2山東大學(xué)醫(yī)學(xué)院2013級臨床醫(yī)學(xué)系,濟(jì)南 250012)
隨著文拉法辛在臨床上的廣泛應(yīng)用,對其不良反應(yīng)的認(rèn)識也不斷深入,現(xiàn)對文拉法辛所致泌尿生殖系統(tǒng)、內(nèi)分泌代謝系統(tǒng)、血液系統(tǒng)、神經(jīng)系統(tǒng)不良反應(yīng)、5-羥色胺(5-HT)綜合征、橫紋肌溶解癥、精神方面不良反應(yīng)和撤藥綜合征等概述如下。
Selvaraj 等報道1例66歲男性抑郁障礙患者應(yīng)用文拉法辛75mg/d 1周內(nèi)出現(xiàn)尿失禁,無論白天還是夜間均有不自主的尿失禁癥狀,停用文拉法辛后恢復(fù)[1]。Polimeni 等報道1例56歲女性反應(yīng)性抑郁患者應(yīng)用文拉法辛75mg/d治療30天后出現(xiàn)尿失禁,停藥48小時癥狀緩解,其后應(yīng)用舍曲林治療未再出現(xiàn)[2]。孫振曉等報道1例38歲女性抑郁障礙患者,應(yīng)用文拉法辛治療,首劑25mg,每日2次,4天后增至50mg,每日2次,增量后次日出現(xiàn)尿頻尿急。繼之出現(xiàn)尿失禁,停用文拉法辛4天后尿失禁消失,改用艾司西酞普蘭治療后未再出現(xiàn)尿失禁[3]。
汪春運(yùn)報道1例15歲男性抑郁障礙患者,應(yīng)用文拉法辛25mg,每日3次治療,4天后出現(xiàn)尿頻尿急,減至25mg,每日2次,4天后尿路癥狀消失,再次增至25mg,每日3次,3天后又出現(xiàn)尿頻尿急,再度減至25mg,每日2次,2天后尿路癥狀消失[4]。
Benazzi報道文拉法辛與氟哌啶醇聯(lián)用致尿潴留1例[5]。
已有文拉法辛致男性自發(fā)性性高潮[6]、性欲亢進(jìn)[7]、陰莖異常勃起[8,9]及射精疼痛[10]的報道。
Berilgen報道1例偏頭痛患者應(yīng)用文拉法辛治療后出現(xiàn)晚發(fā)性乳溢及月經(jīng)過多[11]。Sternbach 報道文拉法辛致乳溢1例[12]。
Karakurt等報道1例19歲男性廣泛性焦慮障礙患者應(yīng)用文拉法辛150mg/d治療3個月后出現(xiàn)男性乳房發(fā)育,無乳溢,實(shí)驗(yàn)室檢查顯示血清催乳素、雌二醇和黃體生成素水平升高。停用文拉法辛后,腫塊縮小,激素水平恢復(fù)正常[13]。
Meyer 等報道1例74歲女性慢性阻塞性肺病患者因呼吸困難入院,臨床及實(shí)驗(yàn)室檢查提示肺部感染而應(yīng)用抗生素治療。該患者因中重度抑郁發(fā)作而使用文拉法辛治療3周,后出現(xiàn)低鈉血癥,血鈉降至108 mmol/L,CT及實(shí)驗(yàn)室檢查排除腦部及肺部、內(nèi)分泌病變所致低鈉血癥,考慮為文拉法辛所致抗利尿激素分泌不當(dāng)綜合征。在未停用文拉法辛,也未嚴(yán)格限制進(jìn)水量的情況下,患者又出現(xiàn)全身性癲癇發(fā)作。后應(yīng)用托伐普坦治療,48小時內(nèi)血鈉升至131mmol/L,也未再出現(xiàn)癲癇發(fā)作[14]。
Roxanas等報道58例65歲以上患者服用文拉法辛后,10例(17.2%)出現(xiàn)低鈉血癥,均發(fā)生于開始應(yīng)用文拉法辛后數(shù)天。這可能與非抑制性抗利尿激素分泌有關(guān)。因其血漿滲透壓低,通過限制液體進(jìn)入,2周內(nèi)恢復(fù)[15]。Grover 等報道文拉法辛引起低鈉血癥表現(xiàn)為緊張癥1例[16]。
梁英等報道1例64歲男性抑郁障礙患者應(yīng)用文拉法辛緩釋膠囊漸增至150mg/d治療,至第5周又增至225mg/d,增加劑量后第2天夜間及第3天清晨分別2次嘔血,每次量約20ml,呈深紅色,血常規(guī)、生化、電解質(zhì)和凝血功能檢查等未見異常,腫瘤標(biāo)志物陰性,胸片檢查亦未發(fā)現(xiàn)異常,將文拉法辛緩釋膠囊減至150mg/d,未再出現(xiàn)嘔血[17]。Ghio 等報道1例84歲女性應(yīng)用文拉法辛導(dǎo)致上消化道出血[18]。也有文拉法辛致瘀斑[19,20]、牙齦出血[21]和陰道出血[22]等的報道。
Lucht 等報道米安色林與文拉法辛聯(lián)用致粒細(xì)胞缺乏癥1例[23]。
Dutra 等報道1例混合型癡呆患者應(yīng)用文拉法辛治療發(fā)生肌陣攣[24]。
García-Parajuá 等報道文拉法辛致類帕金森綜合征1例[25]。Grover等報道1例33歲女性Crohn病伴發(fā)復(fù)發(fā)性抑郁障礙患者既往應(yīng)用文拉法辛75mg/d治療,患者抑郁癥狀未完全緩解,將文拉法辛增至225mg/d治療,在增加劑量后48小時內(nèi),患者出現(xiàn)靜坐不能,停用后緩解[26]。Lee 等報道文拉法辛致遲發(fā)性眼瞼痙攣 1 例[27]。
5-HT能藥物因過度激動腦干和脊索的5-HT1A、5-HT2和5-HT3受體,引起5-HT綜合征,表現(xiàn)為精神狀態(tài)和行為的改變,運(yùn)動系統(tǒng)功能改變,植物神經(jīng)功能紊亂等癥狀[28]。Pan 等報道1例29歲女性抑郁障礙患者在應(yīng)用文拉法辛37.5mg/d治療期間發(fā)生5-HT綜合征,表現(xiàn)不安、震顫、多汗、嘔吐、共濟(jì)失調(diào)、心動過速及肌陣攣,停用文拉法辛并應(yīng)用普魯氯嗪及勞拉西泮治療2小時后恢復(fù)。2周后患者應(yīng)用氟西汀20mg/d治療未見不良反應(yīng)[29]。5-HT綜合征多為合并用藥引起,Rajapakse 等報道1例43歲男性特發(fā)性帕金森病患者,在應(yīng)用多巴胺能藥物治療期間,因抑郁合用文拉法辛治療2周后,出現(xiàn)意識障礙、激越、多汗和運(yùn)動過度入院,并出現(xiàn)嚴(yán)重橫紋肌溶解及急性腎功能衰竭,診斷為5-HT綜合征[30]。已有文拉法辛合并米氮平[31-32]、文拉法辛合并曲馬多[33]、文拉法辛合并鋰鹽[34-36]、文拉法辛合并鈣神經(jīng)蛋白抑制劑[37]、文拉法辛合并美沙酮、環(huán)丙沙星[38]、文拉法辛合并曲馬多、米氮平[39]、文拉法辛合并鋰鹽、丙戊酸鹽[40]、文拉法辛合并單一劑量復(fù)合阿莫西林-克拉維酸[41]、文拉法辛合并苯環(huán)丙胺[42,43]、文拉法辛合并阿米替林、哌替啶[44]、文拉法辛合并苯乙肼[45]、文拉法辛合并氯米帕明[46]等引起5-HT綜合征的報道。
Huang等報道1例21歲女性雙相抑郁患者應(yīng)用低劑量文拉法辛后出現(xiàn)嚴(yán)重橫紋肌溶解,幾天內(nèi)血清肌酸激酶水平增至18711U/L[47]。
至今已有2例文拉法辛致譫妄的報道[48-49]。
Angelo等報道文拉法辛致感覺異常1例。該例系年輕男性抑郁障礙患者應(yīng)用文拉法辛緩釋劑37.5mg/d治療,漸增至150mg/d,患者出現(xiàn)上肢刺痛、麻木和瘙癢,將劑量減至75mg/d,上肢刺痛、麻木和瘙癢癥狀消失。由于患者仍存在抑郁癥狀,又將劑量再增至150mg/d,患者上肢癥狀再現(xiàn),減至75mg/d后,癥狀又消失[50]。
Tripp等報道1例44歲男性酒精依賴患者,因伴發(fā)抑郁應(yīng)用文拉法辛75mg/d治療,1周后患者出現(xiàn)視幻覺,幻覺持續(xù)1周后消失,期間文拉法辛劑量保持不變[51]。Jacob 等報道1例17歲男孩應(yīng)用文拉法辛引起復(fù)雜性視幻覺[52]。
Gareri 等報道文拉法辛與普羅帕酮相互作用出現(xiàn)幻覺及精神運(yùn)動性激越1例?;颊邽?5歲女性,曾應(yīng)用舍曲林治療6個月,曾因高血壓、室上性心動過速、慢性支氣管炎及關(guān)節(jié)炎,服用雷米普利、噻氯匹定托拉塞米、茶堿、對乙酰氨基酚和三唑侖等藥物治療?;颊咭苍鴳?yīng)用普羅帕酮治療3年,用法為150mg,每12小時一次。患者血生化檢查正常,顱腦CT檢查顯示皮質(zhì)萎縮。因舍曲林療效不佳,換用文拉法辛75mg/d,其他藥物不變,4周后增至150mg/d,此劑量10天后患者出現(xiàn)視幻覺持續(xù)約2小時,并在晚上出現(xiàn)精神運(yùn)動性激越,停用文拉法辛后,幻覺及精神運(yùn)動性激越在4天內(nèi)緩解[53]。
Safeekh 等報道1例32歲男性社交恐懼癥患者應(yīng)用文拉法辛150mg/d治療后出現(xiàn)被害妄想,停藥后恢復(fù),應(yīng)用艾司西酞普蘭治療后未再出現(xiàn)[54]。Admou 等報道1例39歲女性抑郁障礙患者在應(yīng)用文拉法辛225-300mg/d治療期間出現(xiàn)鐘情妄想,劑量減至75-150mg/d后消失[55]。文拉法辛引起精神病性癥狀的機(jī)制可能與高劑量文拉法辛具有多巴胺再攝取抑制作用有關(guān)。Adamou等報道高劑量文拉法辛致色情狂1例[56]。
文拉法辛撤藥綜合征的常見臨床表現(xiàn)為胃腸道癥狀,如惡心、嘔吐和腹瀉等;不平衡感,如頭昏、頭重腳輕和眩暈等;一般軀體癥狀,如嗜睡、流感樣癥狀、頭痛、震顫、出汗和厭食等;感覺癥狀如感覺倒錯、麻木、電擊樣感覺、頭部“急流”感覺(rushing noise)和視力模糊等;情感癥狀,如易激惹、焦慮/激越、情緒低落和哭泣等;睡眠障礙,如失眠、噩夢和多夢等[57]。也有文拉法辛撤藥出現(xiàn)躁狂[58]、耳鳴[59]、發(fā)作性睡眠[60]、持續(xù)后像[61]、遺精[62]、譫妄[63]及自殺意念[64]等的報道。
尚有文拉法辛致盜竊癖[65]、腮腺腫大[66]、大腦血管收縮綜合征[67]、夜間磨牙[68-70]、耳鳴[71-72]、乳房疼痛[73]、脫發(fā)[74-75]、銀屑病樣掌跖角皮癥及指甲下角化過度[76]、局灶性肌炎[77]和誘發(fā)乳糜瀉有關(guān)的顯微鏡結(jié)腸炎[78]等方面的報道。
臨床醫(yī)生在使用文拉法辛?xí)r,應(yīng)嚴(yán)格掌握藥物治療的適應(yīng)證和禁忌證,避免濫用藥物,并應(yīng)嚴(yán)密觀察藥物不良反應(yīng),及時發(fā)現(xiàn),及時處理,確保用藥安全。
[1]Selvaraj V,Gunasekar P,Kumar S,et al.Urinary Incontinence due to Overactive Detrusor Muscle: A Rare Side Effect of Venlafaxine[J]. Case Rep Urol,2015,2015:690931.
[2]Polimeni G,Salvo F,Cutroneo P,et al. Venlafaxine-induced urinary incontinence resolved after switching to sertraline[J]. Clin Neuropharmac ol,2005,28(5):247-248.
[3]孫振曉,于相芬.文拉法辛引起尿失禁[J].臨床精神醫(yī)學(xué)雜志,2011,21(5):301.
[4]汪春運(yùn).每日口服文拉法辛75mg出現(xiàn)尿路癥狀1例[J].中國新藥與臨床雜志,2005,24(4):331.
[5]Benazzi F. Urinary retention with venlafaxine-haloperidol combination[J]. Pha rmacopsychiatry,1997,30(1):27.
[6]Ravsten DV,Smith NB,Thatcher GW. Spontaneous male orgasm in association with venlafaxine[J]. Am Fam Physician,1997,55(5):1561, 1564, 1574.
[7]Warren MB. Venlafaxine-Associated Euprolactinemic Galactorrhea and Hypersexuality: A Case Report and Review of the Literature[J]. J Clin Psych opharmacol,2016,36(4):399-400.
[8]Samuel RZ. Priapism associated with venlafaxine use[J]. J Am Acad Child Adolesc Psychiatry,2000,39(1):16-17.
[9]Bolukbasi O,Akyol A. Spontaneous erections and libido increase associated with venlafaxine[J]. Eur J Neurol,1999,6(4):527-528.
[10]Michael A. Venlafaxine-induced painful ejaculation[J]. Br J Psychiatry,2000,177:282.
[11]Berilgen MS. Late-onset galactorrhea and menometrorrhagia with venlafaxine use in a migraine patient[J]. J Clin Psychopharmacol, 2010, 30(6):753-754.
[12]Sternbach H. Venlafaxine-induced galactorrhea[J]. J Clin Psychopharmac ol,2003,23(1):109-110.
[13]Karakurt F,Kargili A,Uz B,et al.Venlafaxine-induced gynecomastia in a young patient: a case report[J]. Clin Neuropharmacol, 2009, 32(1):51-52.
[14]Meyer I,Frank D,Janssens U. A case of venlafaxine-induced syndrome of inappropriate ADH secretion (SIADH) - treatment with tolvaptan[J]. Dtsch Med Wochenschr,2012,137(21):1096-1099.
[15]Roxanas M,Hibbert E,Field M.Venlafaxine hyponatraemia: incidence,mechanism and management[J]. Aust N Z J Psychiatry,2007,41(5):411-418.
[16]Grover S,Somaiya M,Ghormode D.Venlafaxine-associated hyponatremia presenting with catatonia[J]. J Neuropsychiatry Clin Neurosci,2013,25(2):E11-2.
[17]梁英,孫新宇,張?zhí)m蘭.文拉法辛緩釋膠囊致上消化道出血一例[J].國際精神病學(xué)雜志,2014,41(3):191.
[18]Ghio L,Puppo S,Presta A.Venlafaxine and risk of upper gastrointestinal bleeding in elderly depression[J]. Curr Drug Saf,2012,7(5):389-390.
[19]Sarma A,Horne MK .Venlafaxine-induced ecchymoses and impaired platelet aggregation[J]. Eur J Haematol,2006,77(6):533-537.
[20]Carpenter JE,Fombi J,Udoka O,et al. Venlafaxine-Induced Bruising: A Case Report[J]. Prim Care Companion CNS Disord,2016,18(3). doi: 10.4088/PCC.15l01886.
[21]Yavasoglu I,Kadikoylu G,Bolaman Z. Gingival bleeding due to venlafaxine[J].Ann Pharmacother,2008,42(1):144-145.
[22]Linnebur SA,Saseen JJ,Pace WD. Venlafaxine-associated vaginal bleeding[J].Pharmacotherapy, 2002, 22(5): 652-655.
[23]Lucht MJ,Kleinschmidt R,Maier W,et al. Agranulocytosis during treatment with mianserin and venlafaxine[J]. J Clin Psychopharmacol, 2000,20(4):490-491.
[24]Dutra LA,Pedroso JL,Felix EP,et al. Venlafaxine induced-myoclonus in a patient with mixed dementia[J]. Arq Neuropsiquiatr,2008,66(4):894-895.
[25]García-Parajuá P,Alvarez Iniesta I,Magari?os M. Reversible and dose-related parkinsonism induced by venlafaxine[J]. Med Clin(Barc),2003,120(19):759.
[26]Grover S,Valaparla VL. Venlafaxine induced akathisia: a case report[J].Indian J Pharmacol,2014,46(6):660-661.
[27]Lee Y,Yeh WC,Chong MY,et al. Venlafaxine and tardive blepharospasm:a case report[J]. Prog Neuropsychopharmacol Biol Psychiat ry,2007,31(5):1139-1140.
[28]喻東山,葛茂宏.精神科合理用藥手冊[M].2版.南京:江蘇科學(xué)技術(shù)出版社,2011:195-201.
[29]Pan JJ,Shen WW. Serotonin syndrome induced by low-dosevenlafaxine[J].Ann Pharmacother,2003,37(2):209-211.
[30]Rajapakse S,Abeynaike L,Wickramarathne T.Venlafaxine-associated serotonin syndrome causing severe rhabdomyolysis and acute renal failure in a patient with idiopathic Parkinson disease[J]. J Clin Psychopharmacol,2010,30(5):620-622.
[31]Decoutere L,De Winter S,Vander Weyden L,et al.A venlafaxine and mirtazapine-induced serotonin syndrome confirmed by de- and rechallenge[J]. Int J Clin Pharm,2012, 34(5): 686-688.
[32]Dimellis D. Serotonin syndrome produced by a combination of venlafaxine and mirtazapine[J]. World J Biol Psychiatry,2002,3(3):167.
[33]Albi?ana Pérez MS,Cea Pereira L, Bilbao Salcedo J,et al. Possible serotonin syndrome associated with administration of venlafaxine and tramadol[J].Farm Hosp,2012,36(6):548.
[34]Shahani L. Venlafaxine augmentation with lithium leading to serotonin syndrome[J]. J Neuropsychiatry Clin Neurosci,2012,24(3):E47.
[35]Adan-Manes J,Novalbos J,López-Rodríguez R,et al. Lithium and venlafaxine interaction: a case of serotonin syndrome[J]. J Clin Pharm Ther,2006,31(4):397-400.
[36]Mekler G,Woggon B. A case of serotonin syndrome caused by venlafaxine and lithium[J]. Pharmacopsychiatry,1997,30(6):272-273.
[37]Newey CR,Khawam E,Coffman K. Two cases of serotonin syndrome with venlafaxine and calcineurin inhibitors[J]. Psychosomatics, 2011,52(3): 286-290.
[38]Lee J,Franz L,Goforth HW. Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, andvenlafaxine[J]. Psychoso matics,2009,50(6):638-639.
[39]Houlihan DJ. Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine[J]. Ann Pharmacoth er,2004,38(3):411-413.
[40]Liberek C,Aubry JM,Baud P. Manic switch and serotonin syndrome with venlafaxine-lithium-valproate association[J].Therapie,2006,61(6):531-533.
[41]Connor H. Serotonin syndrome after single doses of co-amoxiclav during treatment with venlafaxine[J]. J R Soc Med,2003,96(5):233-234.
[42]Hodgman MJ,Martin TG,Krenzelok EP. Serotonin syndrome due to venlafaxine and maintenance tranylcypromine therapy[J]. Hum Exp Toxicol,1997,16(1):14-17.
[43]Brubacher JR,Hoffman RS,Lurin MJ. Serotonin syndrome from venlafaxinetranylcypromine interaction[J]. Vet Hum Toxicol,1996,38(5):358-361.
[44]Dougherty JA,Young H,Shafi T. Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine[J]. Ann Pharmacoth er,2002,36(10):1647-1648.
[45]Weiner LA,Smythe M,Cisek J. Serotonin syndrome secondary to phenelzinevenlafaxine interaction[J]. Pharmacotherapy,1998,18(2):399-403.
[46]Pinel-Ríos FJ,Pe?uelas-Calvo I,Cerezo-Ramírez N,et al. Serotonin syndrome induced by a combination of venlafaxine and clomipramine. A case report[J]. Actas Esp Psiquiatr, 2016,44(5): 193-202.
[47]Huang SS,Yang HY,Lin YC,et al. Low-dose venlafaxine-induced severe rhabdomyolysis: a case report[J]. Gen Hosp Psychiatry, 2012,34(4):436.e5-7.
[48]del Río-Casanova L,Portela B,Díaz-Llenderrozas F. Venlafaxineinduced delirium mediated by high doses[J]. Rev Neurol,2015 ,60(10):475-477.
[49]Howe C,Ravasia S. Venlafaxine-induced delirium[J]. Can J Psychiatry,2003,48(2):129.
[50]Angelo LJ,Lee KC.Dose-related paresthesias with venlafaxine[J]. J Pharm Pract,2013, 26(5):514-517.
[51]Tripp AC,Golden SA. Transient Complex Visual Hallucinations With Venlafaxine Treatment: A Case Report[J]. Prim Care Companion J Clin Psychiatry, 2009; 11(2): 83.
[52]Jacob MK,Ash P. Venlafaxine-induced complex visual hallucinations in a 17-year-old boy[J]. J Clin Psychiatry,2009, 70(4):601-603.
[53]Gareri P,De Fazio P,Gallelli L,et al.Venlafaxine-propafenone interaction resulting in hallucinations and psychomotor agitation[J]. Ann Pharmacoth er,2008,42(3):434-438.
[54]Safeekh AT,Pinto D. Venlafaxine-induced psychotic symptoms[J]. Indian J Psychiatry,2009,51(4):308-309.
[55]Adamou M, Hale AS. Erotomania induced by venlafaxine: A case study[J].Acta Psychiatr Scand,2003,107:314–317.
[56]Adamou M,Hale AS. Erotomania induced by venlafaxine: a case study[J].Acta Psychiatr Scand,2003,107(4):314-317.
[57]Haddad PM,Anderson IM.Recognising and managing antidepressant discontinuation symptoms[J].Advance in Psychiatric Treatment,2007,13:447-457.
[58]Fava GA,Mangelli L.Mania associated with venlafaxine discontinuation[J].Int J Neuropsychopharmacol,2003, 6(1): 89-90.
[59]Clewes J.A case report of onset of tinnitus following discontinuation of antidepressant and a review of the literature[J].Prim Care Companion CNS Disord,2012,14(1).pii:PCC. 11br01218.
[60]Nissen C,Feige B,Nofzinger E,et al.Transient narcolepsy-cataplexy syndrome after discontinuation of the antidepressant venlafaxine[J].J Sleep Res,2005,14(2):207-208.
[61]Spindler PE.Palinopsia following discontinuation of venlafaxine[J]. Psychiatr Prax,2008,35(5):255-257.
[62]孫振曉.文拉法辛緩釋片撤藥致遺精一例報告[J].精神醫(yī)學(xué)雜志,2015,28(1):73.
[63]van Noorden MS,Vergouwen AC,Koerselman GF.Delirium during withdrawl of venlafaxine[J].Ned Tijdschr Geneeskd,2002, 146(26): 1236- 1237.
[64]Stone TE,Swanson C,Feldman MD.Venlafaxine discontinuation syndrome and suicidal ideation:a case series[J].J Clin Psychopharmacol,2007,27(1):94-95.
[65]Demartini B,D’Agostino A,Basi C,et al. A case of venlafaxine-induced kleptomania[J]. Eur J Clin Pharmacol,2016,72(4):509-510.
[66]Bonnet U,Khalil-Boutros Y.Acute bilateral parotitis occurring during venlafaxine titration in an adolescent female with major depression[J]. Phar macopsychiatry,2014,47(1):36-38.
[67]Davies G,Wilson H,Wilhelm T,et al. The reversible cerebral vasoconstriction syndrome in association with venlafaxine and methenamine[J]. BMJ Case Rep,2013 Jun 13;2013. pii: bcr2013009701.
[68]Alonso-Navarro H,Martín-Prieto M,Ruiz-Ezquerro JJ,et al.Bruxism possibly induced by venlafaxine[J]. Clin Neuropharmac ol,2009,32(2):111-112.
[69]Kuloglu M,Ekinci O,Caykoylu A. Venlafaxine-associated nocturnal bruxism in a depressive patient successfully treated with buspirone[J]. J Psychophar macol,2010,24(4):627-628.
[70]Sam Padamadan Jose. Venlafaxine-Induced Severe Sleep Bruxism in a Patient with Generalized Anxiety Disorder[J]. Indian J Psychol Med,2015,37(2): 249–250.
[71]Pondrom MF,Brahm NC. Venlafaxine-associated tinnitus[J]. Am J Health Syst Pharm,2009,66(18):1606, 1608.
[72]Ahmad S. Venlafaxine and severe tinnitus[J]. Am Fam Physician,1995,51(8):1830.
[73]Bhatia SC,Gupta S,Theesen KA. Breast pain associated with venlafaxine[J]. J Clin Psychiatry,1996,57(9):423.
[74]Pereira CE,Goldman-Levine JD. Extended-release venlafaxine-induced alopecia[J]. Ann Pharmacother,2007,41(6):1084.
[75]Pitchot W,Ansseau M. Venlafaxine-induced hair loss[J]. Am J Psychiatry,2001, 158(7): 1159-1160.
[76]Dalle S,Becuwe C,Balme B,et al. Venlafaxine-associated psoriasiform palmoplantar keratoderma and subungual hyperkeratosis[J]. Br J Dermatol,2006,154(5):999-1000.
[77]Jewell DP,Thompson IW,Sullivan BA,et al. Reversible focal myositis in a patient taking venlafaxine[J]. Rheumatology (Oxford),2004, 43(12):1590-1593.
[78]Béchade D,Carmoi T,Bonnefoy S,et al. Microscopic colitis associated with celiac disease probably triggered by the administration of venlafaxine[J].Rev Med Interne,2009,30(1):74-77.